The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement

Naoya Nakamura, Hirokazu Nakamine, Jun ichi Tamaru, Shigeo Nakamura, Tadashi Yoshino, Kouichi Ohshima, Masafumi Abe

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

To compare immunophenotypic and molecular features between Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with c-myc rearrangements (c-mycR DLBCL), we analyzed 18 cases of B-cell non-Hodgkin's lymphoma with c-mycR that were confirmed by chromosomal and/or Southern blotting analyses. The cases were histologically classified into 10 BLs and five DLBCLs. The remaining three cases could not be classified because of suboptimal quality of the surgical materials. BLs were from five adults and five children, whereas all DLBCLs were from adults. BLs were positive for CD20 (10/10 cases examined), CD10 (9/10), Bcl-2 (1/9), and Bcl-6 (10/10), whereas they were negative for CD3 (0/10) and EBV (0/8), by Epstein-Barr virus (EBV) EBER-1 RNA in situ hybridization. c-MycR DLBCLs were positive for CD20 (5/5), CD10 (2/5), Bcl-2 (3/4), and Bcl-6 (4/4), whereas none of them were positive for CD3 and EBV. A mean of MIB-1 index (MIB-1+ cells/neoplastic cells, %) of BLs (98.1%) was higher than that of c-mycR DLBCLs (66.3%; P <.0001). Somatic mutation of immunoglobulin heavy-chain gene variable region (VH gene) in BLs (four cases) ranged from 0.7 to 4.9% with an average value of 2.3%, whereas those in DLBCLs (three cases) from 8.2 to 32.0% with an average value of 17.0%. It is, therefore, concluded that a growth fraction of nearly 100%, as well as a monotonous proliferation of medium-sized cells and c-mycR, should be of value in the diagnosis of BL, which is probably different from c-mycR DL-BCL. In addition, CD10+, Bcl-2-, and low frequency of mutation of the VH gene could be helpful for the histologic distinction of BL from (c-mycR) DLBCL.

Original languageEnglish
Pages (from-to)771-776
Number of pages6
JournalModern Pathology
Volume15
Issue number7
DOIs
Publication statusPublished - 2002

Fingerprint

Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
Human Herpesvirus 4
Immunoglobulin Heavy Chain Genes
B-Cell Lymphoma
Mutation Rate
Southern Blotting
Non-Hodgkin's Lymphoma
Genes
In Situ Hybridization
RNA
Mutation
Growth

Keywords

  • Burkitt lymphoma
  • C-myc rearrangement
  • Diffuse large B-cell lymphoma
  • Immunoglobulin heavy chain gene
  • Immunohistochemistry
  • MIB-1
  • Somatic mutation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. / Nakamura, Naoya; Nakamine, Hirokazu; Tamaru, Jun ichi; Nakamura, Shigeo; Yoshino, Tadashi; Ohshima, Kouichi; Abe, Masafumi.

In: Modern Pathology, Vol. 15, No. 7, 2002, p. 771-776.

Research output: Contribution to journalArticle

Nakamura, Naoya ; Nakamine, Hirokazu ; Tamaru, Jun ichi ; Nakamura, Shigeo ; Yoshino, Tadashi ; Ohshima, Kouichi ; Abe, Masafumi. / The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. In: Modern Pathology. 2002 ; Vol. 15, No. 7. pp. 771-776.
@article{3f0bcac944ec4ec9b6011b21fe949a6f,
title = "The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement",
abstract = "To compare immunophenotypic and molecular features between Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with c-myc rearrangements (c-mycR DLBCL), we analyzed 18 cases of B-cell non-Hodgkin's lymphoma with c-mycR that were confirmed by chromosomal and/or Southern blotting analyses. The cases were histologically classified into 10 BLs and five DLBCLs. The remaining three cases could not be classified because of suboptimal quality of the surgical materials. BLs were from five adults and five children, whereas all DLBCLs were from adults. BLs were positive for CD20 (10/10 cases examined), CD10 (9/10), Bcl-2 (1/9), and Bcl-6 (10/10), whereas they were negative for CD3 (0/10) and EBV (0/8), by Epstein-Barr virus (EBV) EBER-1 RNA in situ hybridization. c-MycR DLBCLs were positive for CD20 (5/5), CD10 (2/5), Bcl-2 (3/4), and Bcl-6 (4/4), whereas none of them were positive for CD3 and EBV. A mean of MIB-1 index (MIB-1+ cells/neoplastic cells, {\%}) of BLs (98.1{\%}) was higher than that of c-mycR DLBCLs (66.3{\%}; P <.0001). Somatic mutation of immunoglobulin heavy-chain gene variable region (VH gene) in BLs (four cases) ranged from 0.7 to 4.9{\%} with an average value of 2.3{\%}, whereas those in DLBCLs (three cases) from 8.2 to 32.0{\%} with an average value of 17.0{\%}. It is, therefore, concluded that a growth fraction of nearly 100{\%}, as well as a monotonous proliferation of medium-sized cells and c-mycR, should be of value in the diagnosis of BL, which is probably different from c-mycR DL-BCL. In addition, CD10+, Bcl-2-, and low frequency of mutation of the VH gene could be helpful for the histologic distinction of BL from (c-mycR) DLBCL.",
keywords = "Burkitt lymphoma, C-myc rearrangement, Diffuse large B-cell lymphoma, Immunoglobulin heavy chain gene, Immunohistochemistry, MIB-1, Somatic mutation",
author = "Naoya Nakamura and Hirokazu Nakamine and Tamaru, {Jun ichi} and Shigeo Nakamura and Tadashi Yoshino and Kouichi Ohshima and Masafumi Abe",
year = "2002",
doi = "10.1097/01.MP.0000019577.73786.64",
language = "English",
volume = "15",
pages = "771--776",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement

AU - Nakamura, Naoya

AU - Nakamine, Hirokazu

AU - Tamaru, Jun ichi

AU - Nakamura, Shigeo

AU - Yoshino, Tadashi

AU - Ohshima, Kouichi

AU - Abe, Masafumi

PY - 2002

Y1 - 2002

N2 - To compare immunophenotypic and molecular features between Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with c-myc rearrangements (c-mycR DLBCL), we analyzed 18 cases of B-cell non-Hodgkin's lymphoma with c-mycR that were confirmed by chromosomal and/or Southern blotting analyses. The cases were histologically classified into 10 BLs and five DLBCLs. The remaining three cases could not be classified because of suboptimal quality of the surgical materials. BLs were from five adults and five children, whereas all DLBCLs were from adults. BLs were positive for CD20 (10/10 cases examined), CD10 (9/10), Bcl-2 (1/9), and Bcl-6 (10/10), whereas they were negative for CD3 (0/10) and EBV (0/8), by Epstein-Barr virus (EBV) EBER-1 RNA in situ hybridization. c-MycR DLBCLs were positive for CD20 (5/5), CD10 (2/5), Bcl-2 (3/4), and Bcl-6 (4/4), whereas none of them were positive for CD3 and EBV. A mean of MIB-1 index (MIB-1+ cells/neoplastic cells, %) of BLs (98.1%) was higher than that of c-mycR DLBCLs (66.3%; P <.0001). Somatic mutation of immunoglobulin heavy-chain gene variable region (VH gene) in BLs (four cases) ranged from 0.7 to 4.9% with an average value of 2.3%, whereas those in DLBCLs (three cases) from 8.2 to 32.0% with an average value of 17.0%. It is, therefore, concluded that a growth fraction of nearly 100%, as well as a monotonous proliferation of medium-sized cells and c-mycR, should be of value in the diagnosis of BL, which is probably different from c-mycR DL-BCL. In addition, CD10+, Bcl-2-, and low frequency of mutation of the VH gene could be helpful for the histologic distinction of BL from (c-mycR) DLBCL.

AB - To compare immunophenotypic and molecular features between Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) with c-myc rearrangements (c-mycR DLBCL), we analyzed 18 cases of B-cell non-Hodgkin's lymphoma with c-mycR that were confirmed by chromosomal and/or Southern blotting analyses. The cases were histologically classified into 10 BLs and five DLBCLs. The remaining three cases could not be classified because of suboptimal quality of the surgical materials. BLs were from five adults and five children, whereas all DLBCLs were from adults. BLs were positive for CD20 (10/10 cases examined), CD10 (9/10), Bcl-2 (1/9), and Bcl-6 (10/10), whereas they were negative for CD3 (0/10) and EBV (0/8), by Epstein-Barr virus (EBV) EBER-1 RNA in situ hybridization. c-MycR DLBCLs were positive for CD20 (5/5), CD10 (2/5), Bcl-2 (3/4), and Bcl-6 (4/4), whereas none of them were positive for CD3 and EBV. A mean of MIB-1 index (MIB-1+ cells/neoplastic cells, %) of BLs (98.1%) was higher than that of c-mycR DLBCLs (66.3%; P <.0001). Somatic mutation of immunoglobulin heavy-chain gene variable region (VH gene) in BLs (four cases) ranged from 0.7 to 4.9% with an average value of 2.3%, whereas those in DLBCLs (three cases) from 8.2 to 32.0% with an average value of 17.0%. It is, therefore, concluded that a growth fraction of nearly 100%, as well as a monotonous proliferation of medium-sized cells and c-mycR, should be of value in the diagnosis of BL, which is probably different from c-mycR DL-BCL. In addition, CD10+, Bcl-2-, and low frequency of mutation of the VH gene could be helpful for the histologic distinction of BL from (c-mycR) DLBCL.

KW - Burkitt lymphoma

KW - C-myc rearrangement

KW - Diffuse large B-cell lymphoma

KW - Immunoglobulin heavy chain gene

KW - Immunohistochemistry

KW - MIB-1

KW - Somatic mutation

UR - http://www.scopus.com/inward/record.url?scp=0036074344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036074344&partnerID=8YFLogxK

U2 - 10.1097/01.MP.0000019577.73786.64

DO - 10.1097/01.MP.0000019577.73786.64

M3 - Article

VL - 15

SP - 771

EP - 776

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 7

ER -